What did @marys.online.spac actually say?
She received NAD+, KPV, and what she called "MOTZY" (likely BPC-157 or a similar peptide, though the name is unclear from the transcript) in the mail and plans to start them one at a time. She said she's dealing with "crazy eczema" and low energy, and she wants to see if these compounds will "help with inflammation." She's not claiming to cure anything, just documenting a personal experiment. That framing is actually more responsible than most peptide content on TikTok.
Her plan: start NAD+ first, wait a week, then add KPV. She explicitly says to listen to your body and go one at a time so you can identify reactions. That's genuinely reasonable advice for anyone trialing experimental compounds, even if the compounds themselves are another question entirely.
Does the science back this up?
For KPV specifically, there's real preclinical signal for anti-inflammatory effects, but human trial data is thin. For NAD+, the research is more developed, though still debated. The confidence level on both is lower than TikTok enthusiasm suggests.
KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone. Animal studies, including work by Dalmasso et al. (2008, Journal of Molecular Medicine), showed KPV reduced intestinal inflammation in mice models of colitis. Skin-specific data for eczema in humans is essentially nonexistent in published literature. The leap from mouse gut inflammation to human eczema relief is a big one.
NAD+ supplementation has more traction. A randomized controlled trial by Elhassan et al. (2019, Cell Reports) found that oral NMN (an NAD+ precursor) increased blood NAD+ levels in older adults. Whether that translates to meaningful energy improvement in otherwise healthy people is far less clear. Most "energy" claims in this space are extrapolated from cellular metabolism theory, not clinical outcomes.
What did they get wrong (or right)?
She got the protocol approach right. Starting compounds sequentially rather than stacking them all at once is exactly what any responsible self-experimenter should do. Most peptide content on social media encourages stacking multiple compounds immediately, which makes it impossible to attribute effects or side effects to anything specific.
What's missing is a meaningful acknowledgment that these compounds are not FDA-approved for the conditions she's describing. KPV is not a recognized treatment for eczema. NAD+ is not a recognized treatment for fatigue. Taking unregulated peptides ordered online, without confirmed purity or dosing verification, carries real risk. The compounds may not contain what the label says. Peptide purity and concentration can vary significantly between suppliers, and without certificate of analysis review from an accredited lab, there's no way to verify what she's actually injecting or taking.
She doesn't tell viewers where she ordered these, what form they're in (oral, injectable, topical), or whether she consulted a physician. Those are meaningful gaps for a video that 22,600 people watched.
What should you actually know?
If you have chronic eczema, there are legitimate, evidence-backed treatments available through licensed dermatologists, including dupilumab (a biologic), topical corticosteroids, and newer JAK inhibitors. None of those require ordering from an online peptide supplier. Skipping established options to trial unregulated peptides is not a neutral choice, it's a tradeoff with real unknowns.
NAD+ precursors like NMN and NR are available as dietary supplements in Canada and the US, and they carry a more reasonable safety profile than injectable peptides. If someone is interested in NAD+ for energy or longevity, that's a lower-risk entry point than whatever form she received in the mail. KPV research is genuinely interesting at a preclinical level, but "interesting in mice" is a long way from "use this on your eczema."
The one-at-a-time approach she describes is the right instinct. The missing piece is medical oversight. A physician or nurse practitioner familiar with peptide therapy can order baseline labs, confirm compound sourcing, and monitor for adverse effects. That's not bureaucratic gatekeeping, it's basic harm reduction.